down arrow

Emcure Pharma

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE168P01015
  • NSEID: EMCURE
  • BSEID: 544210
INR
1,391.40
-12.85 (-0.92%)
BSENSE

Dec 05

BSE+NSE Vol: 4.57 k

Click here to access the older version
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationHalf Yearly Results
Results Snapshot
Figures in Cr
Consolidate Half Yearly Results
Sep'25
Sep'24
Sep'23
Net Sales
4,370.36
3,817.12
3,219.25
Other Operating Income
0.00
0.00
0.00
Total Operating income
4,370.36
3,817.12
3,219.25
Raw Material Cost
852.96
723.20
659.22
Purchase of Finished goods
1,175.65
882.45
520.59
(Increase) / Decrease In Stocks
-337.07
-133.88
2.88
Employee Cost
778.09
705.99
621.49
Power Cost
0.00
0.00
0.00
Manufacturing Expenses
0.00
0.00
0.01
Selling and Distribution Expenses
0.00
0.00
0.00
Other Expenses
1,008.48
922.17
790.41
Total Expenditure (Excl Depreciation)
3,478.11
3,099.93
2,594.60
Operating Profit (PBDIT) excl Other Income
892.25
717.19
624.65
Other Income
6.82
59.10
16.31
Operating Profit (PBDIT)
899.07
776.29
640.96
Interest
59.30
104.98
111.01
Exceptional Items
-3.50
0.00
-3.13
Gross Profit (PBDT)
836.27
671.31
526.82
Depreciation
204.10
190.49
137.45
Profit Before Tax
632.18
480.82
389.37
Tax
166.01
126.68
102.57
Provisions and contingencies
0.00
0.00
0.00
Profit After Tax
466.16
354.14
286.80
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
Net Profit
466.16
354.14
286.80
Share in Profit of Associates
0.00
0.00
0.00
Minority Interest
-15.75
-15.49
-17.24
Other related items
0.00
0.00
0.00
Consolidated Net Profit
450.42
338.65
269.56
Equity Capital
189.57
189.10
180.85
Face Value
10.0
10.0
10.0
Reserves
0.00
0.00
0.00
Earnings per share (EPS)
23.76
17.91
14.91
Diluted Earnings per share
23.77
18.33
14.91
Operating Profit Margin (Excl OI)
20.42%
18.79%
19.4%
Gross Profit Margin
19.14%
17.59%
16.36%
PAT Margin
10.67%
9.28%
8.91%
Public Share Holdings (%)
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
Half Yearly Analysis Highlights
stock-summary

Net Sales

Growth in half year ended Sep 2025 is 14.49% vs 18.57% in Sep 2024

stock-summary

Consolidate Net Profit

Growth in half year ended Sep 2025 is 33.00% vs 25.63% in Sep 2024

stock-summary

Operating Profit (PBDIT) excl Other Income

Growth in half year ended Sep 2025 is 24.41% vs 14.81% in Sep 2024

stock-summary

Interest

Growth in half year ended Sep 2025 is -43.51% vs -5.43% in Sep 2024

stock-summary

Operating Profit Margin (Excl OI)

Growth in half year ended Sep 2025 has improved from Sep 2024

Compare Half Yearly Results Of Emcure Pharma With
Markets Mojo
Figures in Cr
Consolidate Half Yearly Results
Markets Mojo
Markets Mojo
Change(INR)
Change(%)
Net Sales
4,370.36
2,178.84
2,191.52
100.58%
Other Operating Income
0.00
0.00
0.00
Total Operating income
4,370.36
2,178.84
2,191.52
100.58%
Raw Material Cost
852.96
466.72
386.24
82.76%
Purchase of Finished goods
1,175.65
270.75
904.90
334.22%
(Increase) / Decrease In Stocks
-337.07
-44.88
-292.19
-651.05%
Employee Cost
778.09
382.55
395.54
103.40%
Power Cost
0.00
0.00
0.00
Manufacturing Expenses
0.00
0.00
0.00
Selling and Distribution Expenses
0.00
0.00
0.00
Other Expenses
1,008.48
493.23
515.25
104.46%
Total Expenditure (Excl Depreciation)
3,478.11
1,568.37
1,909.74
121.77%
Operating Profit (PBDIT) excl Other Income
892.25
610.47
281.78
46.16%
Other Income
6.82
29.89
-23.07
-77.18%
Operating Profit (PBDIT)
899.07
640.36
258.71
40.40%
Interest
59.30
2.46
56.84
2,310.57%
Exceptional Items
-3.50
0.00
-3.50
Gross Profit (PBDT)
836.27
637.90
198.37
31.10%
Depreciation
204.10
87.14
116.96
134.22%
Profit Before Tax
632.18
550.76
81.42
14.78%
Tax
166.01
140.56
25.45
18.11%
Provisions and contingencies
0.00
0.00
0.00
Profit After Tax
466.16
410.20
55.96
13.64%
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
Net Profit
466.16
410.20
55.96
13.64%
Share in Profit of Associates
0.00
0.00
0.00
Minority Interest
-15.75
0.00
-15.75
Other related items
0.00
0.00
0.00
Consolidated Net Profit
450.42
410.20
40.22
9.80%
Equity Capital
189.57
15.66
173.91
1,110.54%
Face Value
10.00
1.00
0.00
Reserves
0.00
0.00
0.00
Earnings per share (EPS)
23.76
26.19
-2.43
-9.28%
Diluted Earnings per share
23.77
25.87
-2.10
-8.12%
Operating Profit Margin (Excl OI)
20.42%
28.02%
0.00
-7.60%
Gross Profit Margin
19.14%
29.28%
0.00
-10.14%
PAT Margin
10.67%
18.83%
0.00
-8.16%
Public Share Holdings (%)
0.00%
0.00%
0.00
0.00%
Pledged Promotor Holding (%)
0.00%
0.00%
0.00
0.00%
Half Yearly - Net Sales
Net Sales 4,370.36 Cr
in Sep 2025

Figures in Cr
stock-summary

Growth in half year ended Sep 2025 is 14.49% vs 18.57% in Sep 2024

Half Yearly - Consolidate Net Profit
Consolidate Net Profit 450.42 Cr
in Sep 2025

Figures in Cr
stock-summary

Growth in half year ended Sep 2025 is 33.00% vs 25.63% in Sep 2024

Half Yearly - Operating Profit (PBDIT)
Operating Profit (PBDIT) 892.25 Cr
in Sep 2025

Figures in Cr
stock-summary

Growth in half year ended Sep 2025 is 24.41% vs 14.81% in Sep 2024

Half Yearly - Interest
Interest 59.30 Cr
in Sep 2025

Figures in Cr
stock-summary

Growth in half year ended Sep 2025 is -43.51% vs -5.43% in Sep 2024

Half Yearly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 20.42%
in Sep 2025

Figures in %
stock-summary

Growth in half year ended Sep 2025 has improved from Sep 2024

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."